Biotek-snakken — August 2019
-
Alligator - ny aftale: http://www.proinvestor.com/investornyt/634384/alligator-tecknar-avtal-i-kina-aktien-lyfter
-
Next up is Zymeworks (ZYME). Citigroup takes their price target all the way up to $49 from $22 previously while maintaining their Buy rating. Citi's analyst states 'Despite the shares rallying 70% year-to-date, investors need to pay closer attention to Zymeworks' HER2 antibody-drug-conjugate ZW49, Nochomovitz tells investors in a research note.
-
Nu har vi set Daiichi Sankyo hæve barren for effekt med ADC, men bivirkningsprofilen stadig tung. Lad os håbe at Zymeworks har fundet vejen til både at hæve effekten og holde bivirkningerne på afstand med ZW49. De prækliniske data ser i hvert fald lovende ud. Der skulle komme de første kliniske data på ZW49 i år !
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
men græder samtidigt over jeg er for dårligt til at supplere.